Ablynx’ vobarilizumab fails in lupus trial
Ablynx’ vobarilizumab has failed to hit targets in a mid-stage trial assessing its safety and effectiveness as a treatment for systemic lupus erythematosus (SLE).
Read More
Tag: vobarilizumab
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
